



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Yuri Bereznitski, et al.

Serial No.

10/587,110

Filed:

July 24, 2006

For: NOVEL CRYSTALLINE FORMS OF AN INHIBITOR OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE

TYPE1

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Art Unit: To Be Assigned

Examiner:

To Be Assigned

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR 1.97**

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

Date 10/16/06

Computer generated form "IDS Letter" (IDS Folder). Merck & Co., Inc., 09/08/2005

RELATED APPLICATION

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

U. S. SERIAL NUMBER	FILING DATE	MERCK CASE	
If this is inconvenient, additional copies will be submitted upon reques	t.		
6. In accordance with 37 C.F.R. 1.97, (check one)			
the attached information is filed within three months of the filing d	ate of the captioned case.		
the attached information is filed more than three months after the Office Action on the merits.	filing date but prior to the m	ailing of a first	
the attached information is filed before the mailing of a first Office examination under §1.114.	action after the filing of a re	equest for continued	
the attached information is being filed more than three months aff Office Action on the merits, but before the mailing date of a Final otherwise closes prosecution in the application. The enclosed au Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p)	Action, Notice of Allowance, thorization is therefore giver	or an action that	
each item of information contained in this Information Disclosure from a foreign patent office in a counterpart foreign application no Statement.			
each item of information contained in the information disclosure sa foreign patent office in a counterpart application and this comm designated in §1.56(c) more than thirty days prior to the filing of the	unication was not received l	by any individual	
no item of information contained in this Information Disclosure Statement foreign patent office in a counterpart foreign application, and, to the after making reasonable inquiry, was known to any individual design months prior to the filing of this Statement.	e knowledge of the person	signing the certification	
	Respectfully submitted	Je ?	
	By: Richard C. Billups Attorney For App	licant(s)	
	Reg. No. 31,916	ilicarit(3)	
	MERCK & CO., INC.		
	Patent Dept., RY60-30		
	P.O. Box 2000	_	
	Rahway, N.J. 07065-0907	<i>,</i>	
	(732)594- <u>4683</u>		
	Data: 12 / 16 / 2/2		

Approved for use through 09/30/2006. OMB 0651-0031 SUBSTITUTE for PTO/SB/08A (07-06), Information Disclosure Statement by Applicant Patent and Tradernark Office; U.S DEPARTMENT OF COMMERCE **COMPLETE IF KNOWN** Stitute for form 1449A/PTO

THE PROPERTY OF T Application Number 10/587,110 Filing Date July 24, 2006 STATEMENT BY APPLICANT WAS. First Named Inventor Yuri Bereznitski, et al. Group Art Unit To Be Assigned (use as many sheets as neces AGJ) 1 9 2006 Examiner Name To Be Assigned 1 of Sheet Attorney Docket Number 21586P

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
	1	US 6,319,939 B1		Mabire et al	11/20/2001	
		Equivalent of WO 9929674				
	2	US 6,503,935 B1		Altenbach et al	01/07/2003	
		Equivalent of WO 0007997				
	3	US 2003/0073850 A1		Altenbach et al	04/17/2003	
		Equivalent of WO 0160802				
		" . " . " . " . " . " . " . " . " . " .				

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
	1	PCT	WO 01/90094 A1		Biovitrum AB	11/29/2001
	2	PCT	WO 03/004497 A1		Sumitomo Pharmaceuticals Co, Ltd	01/16/2003

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature

Date Considered

					Facilitate Hadrian Office, 0.5 Del Activitati of Continence		
Su	Substitute for form 1449B/PTO			COMPLETE IF KNOWN			
INFORMATION DISCLOSURE				Application Number	10/587,110		
6	STATEMENT BY APPLICANT			Filing Date	July 24, 2006		
3				First Named Inventor	Yuri Bereznitski, et al.		
			,	Group Art Unit	To Be Assigned		
	(use as many sheets as necessary)			Examiner Name	To Be Assigned		
Sheet	2	of	2	Attorney Docket Number	21586P		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.			
	1	Reimlinger, H. et al., "Synthesen von s-Triazolo[3.4-a]isochinolinen" Chem. Ber, Vol, 103, pp1960-1970, 1970			

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.